Growth Divergence: On Holding and Sportradar Surge as Quanterix Pivots
Key Takeaways
- A wave of Q4 2025 earnings reports reveals a stark performance gap between high-margin consumer platforms and specialized technology firms.
- While On Holding and Sportradar delivered record margins and aggressive capital returns, Quanterix and BigBear.ai faced organic declines despite achieving critical regulatory and liquidity milestones.
Mentioned
Key Intelligence
Key Facts
- 1On Holding achieved a record 62.8% annual gross profit margin, exceeding its 2026 target early.
- 2Sportradar increased its share repurchase authorization to $1 billion following a 17% rise in annual revenue.
- 3Quanterix secured a $897 CMS reimbursement rate for its Lucent AD Complete Alzheimer's test.
- 4BigBear.ai eliminated $9 million in annual interest expense by converting 2029 notes to equity.
- 5Paysafe reported that 16% of its 2025 revenue came from new products, up from 2% in 2022.
| Metric | |||
|---|---|---|---|
| FY Revenue | CHF 3.0B | $1.3B | $1.7B |
| Revenue Growth | 30% | 17% | 6% |
| Adj. EBITDA Margin | 18.8% | 23.0% | 25.2% |
Who's Affected
Analysis
The Q4 2025 earnings cycle has highlighted a significant divergence in the performance of mid-cap and growth-oriented firms, particularly those operating at the intersection of consumer demand and specialized technology. On Holding and Sportradar emerged as the clear frontrunners, demonstrating that premium brand positioning and deep data moats can drive record margins even in a complex global macro environment. Conversely, firms like Quanterix and BigBear.ai are navigating a more turbulent path, where topline growth is often decoupled from organic performance as they pivot toward long-term regulatory and operational milestones.
On Holding (ONON) delivered a masterclass in scaling a premium consumer brand. With full-year net sales reaching CHF 3.0 billion—a 30% increase—the company not only surpassed its own guidance but also achieved a record gross profit margin of 62.8%. This performance was fueled by a strategic shift toward direct-to-consumer (D2C) channels, which now account for nearly 42% of global sales. The brand's explosive 70.8% growth in the Asia Pacific region, particularly in China where it secured a top-five ranking on Tmall for high-end footwear, suggests that On is successfully transitioning from a niche running brand to a global lifestyle powerhouse. Co-founder David Allemann and CEO Martin Hoffmann have positioned the company to exceed its 2026 ambitions ahead of schedule, supported by a retail footprint that is growing both in number and in average store size.
While total revenue grew 25% to $43.9 million, the 22% organic decline in its core Simoa and Spatial platforms indicates a significant reliance on diagnostic partnerships rather than broad-based instrument sales.
In the data and analytics sector, Sportradar (SRAD) showcased the immense value of its Managed Trading Services and its recent acquisition of IMG content. The company’s decision to increase its share repurchase authorization from $300 million to $1 billion is a definitive signal of confidence in its cash-flow generation. With U.S. revenue rising 23% and accounting for a quarter of the total business, Sportradar is effectively monetizing the expansion of legal sports betting and digital media. The integration of IMG content is already yielding results, with the company on track for $140 million in revenue synergies by 2026. CEO Carsten Koerl’s focus on high-margin streaming and demand-side platform (DSP) volume—which grew 35%—highlights a shift toward a more diversified, technology-first revenue mix.
What to Watch
Quanterix (QTRX) presents a more complex narrative. While total revenue grew 25% to $43.9 million, the 22% organic decline in its core Simoa and Spatial platforms indicates a significant reliance on diagnostic partnerships rather than broad-based instrument sales. However, the long-term investment thesis for Quanterix was bolstered by a critical regulatory win: the Centers for Medicare & Medicaid Services (CMS) established a national reference price of $897 for the Lucent AD Complete test. This reimbursement milestone, coupled with the FDA 510(k) submission in January 2026, positions the company to transition from a research-heavy entity to a clinical diagnostics leader. CEO Everett Cunningham is clearly prioritizing the Lucent franchise as the primary engine for future growth, even as academic and pharma research spending remains volatile.
The broader market also saw significant balance sheet restructuring. BigBear.ai (BBAI) successfully converted all of its 2029 notes to equity, removing $9 million in annualized interest expense and achieving record liquidity. While revenue dipped due to lower Army program volumes, the company’s expansion into Abu Dhabi and its remediation of material weaknesses suggest a maturing operational structure. Similarly, CPS Tech (CPSH) is preparing for a major capacity ramp, engaging DAO Corporation for a new manufacturing facility to meet demand for its metal matrix composites. Across these reports, a common thread emerges: the Vitality Index—a metric used by Paysafe (PSFE) to track revenue from new products—is becoming a critical KPI for investors. Paysafe saw 16% of its 2025 revenue come from products launched in the last three years, up from just 2% in 2022. This focus on innovation-led growth is likely to be the defining characteristic of the winners in the 2026 fiscal year.